Wonder
Log in
Research Outline
Prepared for Rachel C. | Delivered February 2, 2020
LGM Pharma Competitive Landscape
Review your project details
Goals
Understand LGM Pharma's position in the market including market size and growth, company overview, key competitors, competitor overview, and a media scan of LGM Pharma and it's competitors.
View less
Early Findings
LGM Pharma Overview
LGM Pharma
offers various types of active pharmaceutical ingredients (API) to various pharmaceutical manufacturers.
The company states that its
API production process
is backed by its technical expertise and comprehensive regulatory DMF records.
As per the
company's statement
, its APIs can be used for several R&D phases until commercial manufacturing.
The company also mentioned that its products were produced by their partner production sites who were certified by top health regulatory bodies such as the "
US-FDA, EDQM, TGA
, UK-MHRA, and others."
Furthermore, the company claims that most of the APIs that they produce are made through processes that
does not violate any copyrights
or regulations.
The company is privately held and has around
11-50 employees.
It was founded in
2005.
The company has an estimated revenue of
$38.8 million.
As this is a private company, its market share is
not directly available
in public domains.
Based on the available overall global market size of the API market ($15.15 billion), the global market share of LGM was calculated as follows:
$38.8 million
/
$15.15 billion
= 0.26%
Prasad Rae
is the CEO of LGM Pharma. The company is based in
Kentucky, United States.
The company was
acquired by New Harbor Capital LLC
last November 15, 2017.
Its products include "
therapeutic classifications, R&D APIs
, clinical phase API supplies, commercial stage CGMP APIs, OTC ingredients, pharmacy compounding, and drug delivery systems APIs."
The company also offers services that include "
regulatory support services
, contract research and manufacturing services, and quality commitment."
It also emphasizes that its products were manufactured using
innovative processes.
Some of its clients include
CritiTech Particle Engineering Solutions
,
I
n
s
i
t
u
B
i
o
l
o
g
i
c
s
,
O
r
b
i
s
BioSciences,
O
p
e
r
t
e
c
h
Bio, and
I
l
l
u
s
t
r
i
s
Pharmaceuticals.
Business Wire
published a report on LGM that detailed the new service offerings of the company.
These new offerings include "
market intelligence and marketing support
; identification and qualification of high-quality FDA-inspected API manufacturers; logistics support, such as the importation of APIs in the correct package sizes for the end market; and supplying necessary documentation to fulfill 503B requirements and ensure FDA compliance."
LGM will deliver the new offerings in
partnership with Willow Birch
, its outsourcing partner.
Active Pharmaceutical Ingredients (API) Market Size
The global active pharmaceutical ingredient (API) was worth
$15.15 billion
in 2018.
It is expected to grow at a rate of
6.8%
from 2019 to 2026.
Competitor
T
eva API
is one of the competitors of LGM Pharma in the API sector.
The company stated that it has the largest selection of over
400 premium API
products.
It also serves around
1,100 customers
in over 100 countries.
The company is based in Israel and has
facilities in the United States
and other countries.
The company has an estimated revenue of
$31.1 million.
It has around
153 employees.
View less